

Select abstracts sponsored by Bristol Myers Squibb and the BMS-Pfizer Alliance to be presented at ESC Congress 2025 can be found below. Complete abstracts may be accessed online [here](#). Visit the following [page](#) on BMS.com for more information on Bristol Myers Squibb's scientific approach to and resources on cardiovascular diseases.

Abstract Title	Primary Author	Type	Session Title	Date/Time (CEST)
Camzyos (mavacamten)				
Real-world health status changes with mavacamten in symptomatic obstructive hypertrophic cardiomyopathy (oHCM) – Early findings from COMPASS-HCM	Wang, A	Moderated Poster	Cardiotoxicity and protection: from bench to bedside	Friday, Aug. 29 9:15 AM – 10:00 AM
Sex-disaggregated data in hypertrophic cardiomyopathy: a targeted literature review, meta-analysis, and retrospective cohort study	Lim, VG	Poster	New perspectives in cardiology (1)	Friday, Aug. 29 12:30 PM – 1:15 PM
Real-world outcomes of mavacamten for symptomatic obstructive hypertrophic cardiomyopathy: Global evidence from COLLIGO-HCM	Adler, A	Oral Presentation	Advancing care in hypertrophic cardiomyopathy	Friday, Aug. 29 1:35 PM – 1:45 PM
ODYSSEY-HCM: Mavacamten in nHCM	Desai, M	Late-breaking Oral Presentation	HOT LINE 2	Saturday, Aug. 30 9:08 AM – 9:18 AM
Integrated efficacy and safety analysis of mavacamten monotherapy in patients with obstructive hypertrophic cardiomyopathy	Olivotto, I	Oral Presentation	Precision medicine in hypertrophic cardiomyopathy	Saturday, Aug. 30 2:21 PM – 2:39 PM
Bi-ventricular cardiovascular magnetic resonance strain phenotypes are predictive of cardiovascular outcomes in patients with asymptomatic hypertrophic cardiomyopathy	Sajjad, S	Poster Presentation	Improving outcome prediction in hypertrophic cardiomyopathy	Sunday, Aug. 31 10:15 AM – 11:00 AM
Cardiac biomarkers on mavacamten in nonobstructive HCM: Sub-study of the ODYSSEY-HCM trial	Desai, M	Poster Presentation	New perspectives in cardiology (3)	Sunday, Aug. 31 3:15 PM
Mavacamten treatment in obstructive hypertrophic cardiomyopathy for up to 30 weeks: An integrated analysis of cardiac magnetic resonance data from a diverse population in randomized clinical trials	Kramer, C	Oral Presentation	Hypertrophic cardiomyopathy: from gene to treatment	Sunday, Aug. 31 5:30 PM – 5:40 PM
Echocardiographic changes in nonobstructive hypertrophic cardiomyopathy patients treated with mavacamten: A sub-study of the ODYSSEY-HCM trial	Desai, M	Oral Presentation	Hypertrophic cardiomyopathy: from gene to treatment	Sunday, Aug. 31 6:00 PM – 6:10 PM
Effect of mavacamten on left ventricular myocardial volume, strain and tissue characteristics in patients with hypertrophic cardiomyopathy	Tse, J	Poster Presentation	Management of hypertrophic obstructive cardiomyopathy	Monday, Sept. 1 9:15 AM – 10:00 AM
Mavacamten real-world experience: Insights from the Dutch HCM Network	Zwetsloot, P	Poster Presentation	Myocardial disease and valvular heart disease: miscellany	Monday, Sept. 1 1:15 PM – 2:00 PM
Elquis (apixaban) – Sponsored by the Bristol Myers Squibb-Pfizer Alliance				
Home screening for detection of atrial fibrillation in elderly hypertensive patients	Trafalis, D	Poster	Atrial fibrillation screening	Saturday, Aug. 30

with left atrial enlargement using hand-held medical device, the DEFINE-AF clinical study				12:15 PM – 1:00 PM
Transient new-onset atrial fibrillation after myocardial infarction and adverse outcomes	Fischman, M	Poster	Outcomes in atrial fibrillation	Sunday, Aug. 31 4:15 PM – 5:00 PM
Early Assets				
Cardiac myosin inhibitor MYK-581 prevents development of hypertrophic cardiomyopathy phenotype in human iPSC models	Knollmann, B	Oral Presentation	Molecular and immune mechanisms in cardiomyopathy	Sunday, Aug. 31 9:05 AM – 9:15 AM